Literature DB >> 2835943

Surgical therapy in two patients with pedunculated hepatocellular carcinoma.

M W Moritz1, M Shoji, G A Sicard, R Shioda, K DeSchryver.   

Abstract

Hepatocellular carcinoma (HCC) occurring as an appendage from the main hepatic parenchyma is a rare entity, of which two cases are herein described. Because proper surgical management of this tumor (pedunculated HCC) is unclear, the world's literature was reviewed to determine optimal therapy. Thirty-four cases were documented, including the two cases reported herein. Diagnosis was usually obscure, despite modern invasive and noninvasive methods, and laparotomy or autopsy were required for specific identification of tumor type. Sixteen resections were reported among 18 explorations. One patient had transarterial embolization. Fifteen received medical therapy only. Surgically treated patients usually died of metastatic disease, whereas most medically treated patients died of gastrointestinal or tumor hemorrhage. Pedunculated HCC may be more amenable to curative resection than ordinary HCC due to its unique localization and growth pattern.

Entities:  

Mesh:

Year:  1988        PMID: 2835943     DOI: 10.1001/archsurg.1988.01400300118021

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  3 in total

1.  Blood supply characteristics of pedunculated hepatocellular carcinoma prior to and following transcatheter arterial chemoembolization treatment: An angiographic demonstration.

Authors:  Dexiao Huang; Yong Chen; Qingle Zeng; Jianbo Zhao; Xizhong Wu; Renhua Wu; Yanhao Li
Journal:  Oncol Lett       Date:  2017-12-21       Impact factor: 2.967

2.  TACE plus percutaneous chemotherapy-lipiodol treatment of unresectable pedunculated hepatocellular carcinoma.

Authors:  Dexiao Huang; Yong Chen; Shuo Chen; Qingle Zeng; Jianbo Zhao; Renhua Wu; Yanhao Li
Journal:  Medicine (Baltimore)       Date:  2017-07       Impact factor: 1.889

3.  Pedunculated hepatocellular carcinoma and surgical treatment.

Authors:  T Nishizaki; T Matsumata; E Adachi; H Hayashi; K Sugimachi
Journal:  Br J Cancer       Date:  1993-01       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.